<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661178</url>
  </required_header>
  <id_info>
    <org_study_id>DNDI-EMO-001</org_study_id>
    <secondary_id>2015-003592-29</secondary_id>
    <nct_id>NCT02661178</nct_id>
  </id_info>
  <brief_title>First in Man Clinical Trial of Emodepside (BAY 44-4400)</brief_title>
  <official_title>A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, and pharmacokinetics of single
      ascending doses of emodepside (BAY 44-4400) in healthy male volunteers. This study will also
      conduct an exploratory investigation of the relative bioavailability of emodepside
      administered as tablets and determine the effect of food on the pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by Adverse Events</measure>
    <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
    <description>Deaths, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by Physical and Neurological Examination Findings</measure>
    <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
    <description>Abnormal or clinically significant neurological examination findings during the study or reported as an AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by Vital Signs</measure>
    <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
    <description>Vital signs included heart rate, systolic and diastolic blood pressure,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by 12-lead ECG</measure>
    <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
    <description>The following variables were recorded in 12-lead ECGs and extracted from continuous 12-lead ECG recordings: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by Clinical Laboratory Parameters</measure>
    <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
    <description>Clinical laboratory parameters included hematology, biochemistry, serology and coagulation in blood samples and urinalysis in urine samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as Measured by Ophthalmological Examination Findings in One Study Arm Only</measure>
    <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
    <description>Subjects attended a specialist eye hospital for ophthalmology assessments by a Consultant Ophthalmologist. Opthalmology assessments included:ocular symptoms, past ocular history, auto-refraction, best corrected distance visual acuity, color vision assessment, amsler grid assessment, ocular alignment and ocular motility assessment, confrontation visual field assessment, slit lamp examination (anterior segment), intraocular pressure (Goldmann Tonometry), optical coherence scanning of tomography, post mydriatic ocular media (at Screening visit 2 only) and retinal examination with slit lamp and lens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The AUC∞ of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>The area under the plasma drug concentration versus time curve from time zero to infinity (AUC∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC∞/D of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Dose-normalized area under the plasma drug concentration versus time curve from time zero to infinity (AUC∞/D), calculated as AUC∞/Dose administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Maximum observed plasma concentration (Cmax) was obtained directly from the concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax/D of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Dose-normalized observed maximum plasma concentration (Cmax/D) was calculated as Cmax/Dose administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax, Norm of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>The observed maximum plasma concentration (Cmax) normalized by dose and body weight was calculated as Cmax/(Dose administered*body weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Tmax of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Time to reach maximum plasma concentration (Tmax) was obtained directly from the concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The t½ of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Terminal half-life (t½), calculated according to the equation t½ = ln2/λz, where λz is the apparent terminal elimination rate constant, estimated by linear regression of log-transformed concentration versus time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The MRT of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>The mean residence time (MRT) was calculated as MRT = AUMC/AUC∞, where AUMC is the area under the first moment of the concentration-time curve from zero time (pre-dose) extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The CL/F of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Apparent total clearance from plasma (CL/F) was calculated as CL/F = Dose/AUC∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC 0-24 of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Area under the plasma concentration-time curve from time zero (pre-dose) to 24 h was calculated using the trapezoidal method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC 0-24/D of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Dose-normalized area under the concentration-time curve (AUC) from time zero (pre-dose) to 24 h was calculated as AUC0-24/Dose administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC 24, Norm of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Area under the concentration-time curve from time zero (pre-dose) to 24 h, normalized by dose and body weight (AUC 24, norm) was calculated as AUC0-24/(Dose administered*body weight)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Vz/F of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Apparent volume of distribution (Vz/F) was calculated as Vz/F = Dose/(λz × AUC∞), where λz is the apparent terminal elimination rate constant, estimated by linear regression of log-transformed concentration versus time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC Last of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>The area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t), calculated using the linear trapezoidal method for increasing concentrations and the log trapezoidal method for decreasing concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frel of the IR (Immediate Release) Tablet of Emodepside</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>The average relative bioavailability (Frel) of the IR tablet was calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC Last, Norm of Emodepside in Plasma</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>The area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration normalized by dose and body weight (AUClast/(Dose administered*body weight))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on the Bioavailability (Cmax) of Emodepside (BAY 44-4400) After Single Oral Dose Administered as Solution or IR Tablets in One Arm Only</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Results of the statistical analysis of the effect of food on Emodepside exposure, after a single dose of 10 mg Emodepside LSF solution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on the Bioavailability (AUC24) of Emodepside (BAY 44-4400) After Single Oral Dose Administered as Solution or IR Tablets in One Arm Only</measure>
    <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
    <description>Results of the statistical analysis of the effect of food on Emodepside exposure, after a single dose of 10 mg Emodepside LSF solution.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>emodepside (BAY 44-4400)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 cohorts with single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo of emodepside (BAY 44-4400)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Up to 10 cohorts with single ascending dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emodepside (BAY 44-4400)</intervention_name>
    <arm_group_label>emodepside (BAY 44-4400)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo of emodepside (BAY 44-4400)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, Caucasian volunteers, deemed healthy on the basis of a clinical history,
             physical examination, ECG, vital signs, and laboratory tests of blood and urine.
             Optionally, after further evaluation during the study, at the sponsor's discretion
             other ethnic groups may be recruited.

          -  Aged 18 to 55 years.

          -  With a body mass index (BMI; Quetelet index) in the range of 18 to 30.1 kg/m2 at
             screening.

          -  Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the investigator and
             to participate in, and comply with the requirements of, the entire trial.

          -  Willingness to give written consent to participate, after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             investigator or his delegate

        Exclusion Criteria:

          -  Participation in another clinical trial within 3 months prior and during the study, or
             5-times the half-life of the drug tested in the previous clinical trial, whichever is
             longer (time calculated relative to the last dose in the previous clinical trial)

          -  Clinically relevant abnormal medical history, concurrent medical condition, acute or
             chronic illness or history of chronic illness sufficient to invalidate the subject's
             participation in the trial or make it unnecessarily hazardous.

          -  Surgery (eg stomach bypass) or medical condition that might affect absorption of study
             drug taken orally.

          -  Presence of abnormal physical findings, ECG, or laboratory values at the pre-trial
             screening assessment that could interfere with the objectives of the trial or the
             safety of the subject.

          -  Positive tests for hepatitis B &amp; C, HIV

          -  Presence or history of drug or alcohol abuse during the last 10 years, or intake of
             more than 21 units of alcohol weekly.

          -  Regular daily consumption of more than one liter of xanthine-containing beverages

          -  Regular daily consumption of more than 5 cigarettes daily, or use more than 3 grams
             (1/8 ounce) of tobacco

          -  Use of a prescription medicine during the 28 days before the first dose of trial
             medication or use of an over-the-counter medicine, with the exception of acetaminophen
             (paracetamol), during the 7 days before the first dose of trial medication

          -  Use of dietary supplements or herbal remedies (such as St John's Wort) known to
             interfere with the CYP3A4 and/or P-gp metabolic pathways during the 28 days before the
             first dose of trial medication (see list in Study Procedures Manual)

        Additional exclusion criteria for cohort with ophthalmological assessments:

          -  No contact lenses wear within 1 month prior to first dose of IMP. Contact lenses wear
             is not permitted during the study

          -  Any ocular disorder for which topical ocular therapy is currently or chronically
             prescribed, including inflammatory eye disease (dry eye allergic conjunctivitis
             [seasonal allergic conjunctivitis, vernal keratoconjunctivitis, atopic
             keratoconjunctivitis], uveitis and glaucoma)

          -  Past history of ocular disease requiring ongoing treatment

          -  Past ocular surgery including laser or other refractive corneal surgery

          -  Evidence of eye irritation, visual difficulties, corneal opacity, ocular surface
             (corneal or conjunctival damage, with or without ocular symptoms)

          -  Evidence of narrow anterior chamber angles causing increased risk of acute glaucoma

          -  Evidence of ocular media opacity including lens opacity/vitreous opacities

          -  Evidence of retinal or optic nerve pathology

          -  Evidence of pronounced colour blindness, as indicated by an Ishihara score of 9/13 or
             below
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Boyce, MD, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Monnot</last_name>
    <role>Study Director</role>
    <affiliation>Drugs for Neglected Diseases Initiative</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <results_first_submitted>April 3, 2019</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2020</results_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parasitic Diseases</keyword>
  <keyword>Helminthiasis</keyword>
  <keyword>Nematode Infections</keyword>
  <keyword>Secernentea Infections</keyword>
  <keyword>Spirurida Infections</keyword>
  <keyword>Filariasis</keyword>
  <keyword>Skin Diseases, Parasitic</keyword>
  <keyword>Skin and Connective Tissue Diseases</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Skin Diseases, Infectious</keyword>
  <keyword>Depsipeptides</keyword>
  <keyword>Emodepside</keyword>
  <keyword>Neglected disease</keyword>
  <keyword>Africa</keyword>
  <keyword>New drug</keyword>
  <keyword>Oral drug</keyword>
  <keyword>Parasite</keyword>
  <keyword>Anthelmintic drug</keyword>
  <keyword>Cyclooctadepsipeptide</keyword>
  <keyword>Single ascending dose</keyword>
  <keyword>Volunteers</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Relative bioavailability</keyword>
  <keyword>Onchocerciasis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emodepside</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02661178/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02661178/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>79 healthy subjects were randomized and received study drug. Protocol Enrollment reflects the total number of participants enrolled in both Part 1 (63 participants) and Part 2 (16 participants).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P2">
          <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P3">
          <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P4">
          <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P5">
          <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P6">
          <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P7">
          <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P8">
          <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P9">
          <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P10">
          <title>Placebo Solution, Fasted (Part 1)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P11">
          <title>Placebo Tablet, Fasted (Part 1)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="P12">
          <title>Emodepside 10mg Solution, Fed (Part 2)</title>
          <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="P13">
          <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
          <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="P14">
          <title>Placebo Solution, Fed (Part 2)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="P15">
          <title>Placebo Solution, Fasted (Part 2)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="6"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B2">
          <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B3">
          <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B4">
          <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B5">
          <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B6">
          <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B7">
          <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B8">
          <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B9">
          <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B10">
          <title>Placebo Solution, Fasted (Part 1)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B11">
          <title>Placebo Tablet, Fasted (Part 1)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="B12">
          <title>Emodepside 10mg Solution, Fed (Part 2)</title>
          <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="B13">
          <title>Emodepside 40mg Solution, Fasted, AE Follow-up Arm (Part 2)</title>
          <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="B14">
          <title>Placebo Solution, Fed (Part 2)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="B15">
          <title>Placebo Solution, Fasted (Part 2)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="12"/>
            <count group_id="B11" value="4"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="6"/>
            <count group_id="B14" value="2"/>
            <count group_id="B15" value="2"/>
            <count group_id="B16" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="0"/>
                    <measurement group_id="B2" value="38.6" spread="10.06"/>
                    <measurement group_id="B3" value="34.8" spread="9.20"/>
                    <measurement group_id="B4" value="29.3" spread="8.12"/>
                    <measurement group_id="B5" value="36.8" spread="10.69"/>
                    <measurement group_id="B6" value="34.2" spread="10.55"/>
                    <measurement group_id="B7" value="32.8" spread="9.75"/>
                    <measurement group_id="B8" value="31.3" spread="8.91"/>
                    <measurement group_id="B9" value="30.8" spread="10.83"/>
                    <measurement group_id="B10" value="30.7" spread="7.46"/>
                    <measurement group_id="B11" value="28.0" spread="3.56"/>
                    <measurement group_id="B16" value="32.4" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B12" value="27.7" spread="7.34"/>
                    <measurement group_id="B13" value="38.5" spread="10.67"/>
                    <measurement group_id="B14" value="51.5" spread="0.71"/>
                    <measurement group_id="B15" value="40" spread="11.31"/>
                    <measurement group_id="B16" value="38.3" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B16" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B16" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B16" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B16" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173" spread="0"/>
                    <measurement group_id="B2" value="176.8" spread="4.87"/>
                    <measurement group_id="B3" value="179.8" spread="6.24"/>
                    <measurement group_id="B4" value="175.5" spread="5.82"/>
                    <measurement group_id="B5" value="177.2" spread="10.87"/>
                    <measurement group_id="B6" value="177.2" spread="3.54"/>
                    <measurement group_id="B7" value="179.0" spread="7.51"/>
                    <measurement group_id="B8" value="179.5" spread="7.45"/>
                    <measurement group_id="B9" value="183.3" spread="7.63"/>
                    <measurement group_id="B10" value="180.0" spread="7.98"/>
                    <measurement group_id="B11" value="183.3" spread="2.99"/>
                    <measurement group_id="B16" value="179.1" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B12" value="183.2" spread="6.37"/>
                    <measurement group_id="B13" value="176.0" spread="5.22"/>
                    <measurement group_id="B14" value="178" spread="8.49"/>
                    <measurement group_id="B15" value="181" spread="4.24"/>
                    <measurement group_id="B16" value="179.6" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.00" spread="0"/>
                    <measurement group_id="B2" value="70.64" spread="6.815"/>
                    <measurement group_id="B3" value="75.47" spread="11.331"/>
                    <measurement group_id="B4" value="75.83" spread="3.506"/>
                    <measurement group_id="B5" value="76.56" spread="13.197"/>
                    <measurement group_id="B6" value="74.80" spread="11.383"/>
                    <measurement group_id="B7" value="81.93" spread="10.397"/>
                    <measurement group_id="B8" value="81.73" spread="9.075"/>
                    <measurement group_id="B9" value="83.27" spread="11.267"/>
                    <measurement group_id="B10" value="79.52" spread="10.130"/>
                    <measurement group_id="B11" value="85.15" spread="7.217"/>
                    <measurement group_id="B16" value="78.43" spread="9.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B12" value="82.20" spread="7.979"/>
                    <measurement group_id="B13" value="82.65" spread="13.598"/>
                    <measurement group_id="B14" value="72.8" spread="1.98"/>
                    <measurement group_id="B15" value="83.7" spread="24.75"/>
                    <measurement group_id="B16" value="81.38" spread="11.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <population>Totals were calculated seperately for Parts 1 and 2</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="5"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="12"/>
                    <count group_id="B11" value="4"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="0"/>
                    <count group_id="B14" value="0"/>
                    <count group_id="B15" value="0"/>
                    <count group_id="B16" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.10" spread="0"/>
                    <measurement group_id="B2" value="22.60" spread="2.117"/>
                    <measurement group_id="B3" value="23.30" spread="2.683"/>
                    <measurement group_id="B4" value="24.65" spread="1.162"/>
                    <measurement group_id="B5" value="24.20" spread="1.707"/>
                    <measurement group_id="B6" value="23.75" spread="2.868"/>
                    <measurement group_id="B7" value="25.55" spread="2.651"/>
                    <measurement group_id="B8" value="25.43" spread="3.169"/>
                    <measurement group_id="B9" value="24.72" spread="2.613"/>
                    <measurement group_id="B10" value="24.49" spread="2.131"/>
                    <measurement group_id="B11" value="25.38" spread="2.291"/>
                    <measurement group_id="B16" value="24.41" spread="2.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="6"/>
                    <count group_id="B13" value="6"/>
                    <count group_id="B14" value="2"/>
                    <count group_id="B15" value="2"/>
                    <count group_id="B16" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B12" value="24.5" spread="2.137"/>
                    <measurement group_id="B13" value="26.55" spread="3.213"/>
                    <measurement group_id="B14" value="23.1" spread="2.83"/>
                    <measurement group_id="B15" value="25.4" spread="6.36"/>
                    <measurement group_id="B16" value="25.21" spread="3.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability as Measured by Adverse Events</title>
        <description>Deaths, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)</description>
        <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
        <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.
In Part 2, n=16 (n=16 subjects completed)</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>No AEs were reported for Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O12">
            <title>Placebo Solution, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O13">
            <title>Placebo Tablet, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O14">
            <title>Placebo Solution, Fed (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O15">
            <title>Placebo Solution, Fasted (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Adverse Events</title>
          <description>Deaths, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)</description>
          <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.
In Part 2, n=16 (n=16 subjects completed)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability as Measured by Physical and Neurological Examination Findings</title>
        <description>Abnormal or clinically significant neurological examination findings during the study or reported as an AE</description>
        <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
        <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>No AEs were reported for Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O12">
            <title>Placebo Solution, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O13">
            <title>Placebo Tablet, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O14">
            <title>Placebo Solution, Fed (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O15">
            <title>Placebo Solution, Fasted (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Physical and Neurological Examination Findings</title>
          <description>Abnormal or clinically significant neurological examination findings during the study or reported as an AE</description>
          <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal neurological examination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological examination reported as AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal physcial examination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical examination reported as AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability as Measured by Vital Signs</title>
        <description>Vital signs included heart rate, systolic and diastolic blood pressure,</description>
        <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
        <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O12">
            <title>Placebo Solution, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O13">
            <title>Placebo Tablet, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O14">
            <title>Placebo Solution, Fed (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O15">
            <title>Placebo Solution, Fasted (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Vital Signs</title>
          <description>Vital signs included heart rate, systolic and diastolic blood pressure,</description>
          <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant change in heart rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant change in systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant change in diastolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability as Measured by 12-lead ECG</title>
        <description>The following variables were recorded in 12-lead ECGs and extracted from continuous 12-lead ECG recordings: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.</description>
        <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
        <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O12">
            <title>Placebo Solution, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O13">
            <title>Placebo Tablet, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O14">
            <title>Placebo Solution, Fed (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O15">
            <title>Placebo Solution, Fasted (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by 12-lead ECG</title>
          <description>The following variables were recorded in 12-lead ECGs and extracted from continuous 12-lead ECG recordings: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.</description>
          <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Notable changes in ventricular rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notable changes in PR interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notable changes in QRS interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notable changes in QTcB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notable changes in QTcF interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability as Measured by Clinical Laboratory Parameters</title>
        <description>Clinical laboratory parameters included hematology, biochemistry, serology and coagulation in blood samples and urinalysis in urine samples</description>
        <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
        <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O12">
            <title>Placebo Solution, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O13">
            <title>Placebo Tablet, Fasted (Part 1)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O14">
            <title>Placebo Solution, Fed (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O15">
            <title>Placebo Solution, Fasted (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Clinical Laboratory Parameters</title>
          <description>Clinical laboratory parameters included hematology, biochemistry, serology and coagulation in blood samples and urinalysis in urine samples</description>
          <population>AEs were determined in the Safety Population. In Part 1 n=63 (n=62 subjects completed). One subject in the 1mg emodepside group was withdrawn after receiving 0.1mg emodepside LSF, owing to an AE. He consented to follow-up safety assessment until Day 7 as a 0.1mg emodepside group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant hematological changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant biochemical changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant serological changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant coagulation changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant urinalysis changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability as Measured by Ophthalmological Examination Findings in One Study Arm Only</title>
        <description>Subjects attended a specialist eye hospital for ophthalmology assessments by a Consultant Ophthalmologist. Opthalmology assessments included:ocular symptoms, past ocular history, auto-refraction, best corrected distance visual acuity, color vision assessment, amsler grid assessment, ocular alignment and ocular motility assessment, confrontation visual field assessment, slit lamp examination (anterior segment), intraocular pressure (Goldmann Tonometry), optical coherence scanning of tomography, post mydriatic ocular media (at Screening visit 2 only) and retinal examination with slit lamp and lens.</description>
        <time_frame>Up to 14 days post dose (may be extended to 21 days)</time_frame>
        <population>AEs were determined in the Safety Population. Opthalmology examinations were only performed for the Emodepside 40mg group (n=6) and the corresponding placebo group (n=2)</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Solution, Fasted (Part 2)</title>
            <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Ophthalmological Examination Findings in One Study Arm Only</title>
          <description>Subjects attended a specialist eye hospital for ophthalmology assessments by a Consultant Ophthalmologist. Opthalmology assessments included:ocular symptoms, past ocular history, auto-refraction, best corrected distance visual acuity, color vision assessment, amsler grid assessment, ocular alignment and ocular motility assessment, confrontation visual field assessment, slit lamp examination (anterior segment), intraocular pressure (Goldmann Tonometry), optical coherence scanning of tomography, post mydriatic ocular media (at Screening visit 2 only) and retinal examination with slit lamp and lens.</description>
          <population>AEs were determined in the Safety Population. Opthalmology examinations were only performed for the Emodepside 40mg group (n=6) and the corresponding placebo group (n=2)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant occular symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant best corrected vis acuity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant changes in remaining exams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC∞ of Emodepside in Plasma</title>
        <description>The area under the plasma drug concentration versus time curve from time zero to infinity (AUC∞)</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>It is unacceptable to use AUCinf data if&gt;40% of the AUC has been extrapolated.This is in line with literature(Gabrielson&amp;Weiner, 2000).The AUCinf values with&lt;20% of the area extrapolated (reliable results) have not been summarised in the tables because n is either 1 or 2 per treatment (n=2 only for 1m solution).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC∞ of Emodepside in Plasma</title>
          <description>The area under the plasma drug concentration versus time curve from time zero to infinity (AUC∞)</description>
          <population>It is unacceptable to use AUCinf data if&gt;40% of the AUC has been extrapolated.This is in line with literature(Gabrielson&amp;Weiner, 2000).The AUCinf values with&lt;20% of the area extrapolated (reliable results) have not been summarised in the tables because n is either 1 or 2 per treatment (n=2 only for 1m solution).</population>
          <units>h*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O9" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O10" value="NA" spread="NA">see explanation above</measurement>
                    <measurement group_id="O11" value="NA" spread="NA">see explanation above</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC∞/D of Emodepside in Plasma</title>
        <description>Dose-normalized area under the plasma drug concentration versus time curve from time zero to infinity (AUC∞/D), calculated as AUC∞/Dose administered.</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>It is unacceptable to use AUCinf data if&gt;40% of the AUC has been extrapolated.This is in line with literature(Gabrielson&amp;Weiner, 2000).The AUCinf values with&lt;20% of the area extrapolated (reliable results) have not been summarised in the tables because n is either 1 or 2 per treatment (n=2 only for 1m solution).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC∞/D of Emodepside in Plasma</title>
          <description>Dose-normalized area under the plasma drug concentration versus time curve from time zero to infinity (AUC∞/D), calculated as AUC∞/Dose administered.</description>
          <population>It is unacceptable to use AUCinf data if&gt;40% of the AUC has been extrapolated.This is in line with literature(Gabrielson&amp;Weiner, 2000).The AUCinf values with&lt;20% of the area extrapolated (reliable results) have not been summarised in the tables because n is either 1 or 2 per treatment (n=2 only for 1m solution).</population>
          <units>No values calculated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">see explanation above</measurement>
                    <measurement group_id="O2" value="NA">see explanation above</measurement>
                    <measurement group_id="O3" value="NA">see explanation above</measurement>
                    <measurement group_id="O4" value="NA">see explanation above</measurement>
                    <measurement group_id="O5" value="NA">see explanation above</measurement>
                    <measurement group_id="O6" value="NA">see explanation above</measurement>
                    <measurement group_id="O7" value="NA">see explanation above</measurement>
                    <measurement group_id="O8" value="NA">see explanation above</measurement>
                    <measurement group_id="O9" value="NA">see explanation above</measurement>
                    <measurement group_id="O10" value="NA">see explanation above</measurement>
                    <measurement group_id="O11" value="NA">see explanation above</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax of Emodepside in Plasma</title>
        <description>Maximum observed plasma concentration (Cmax) was obtained directly from the concentration-time data</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration were summarized using PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax of Emodepside in Plasma</title>
          <description>Maximum observed plasma concentration (Cmax) was obtained directly from the concentration-time data</description>
          <population>PK Concentration were summarized using PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="20.8"/>
                    <measurement group_id="O2" value="37.6" spread="15.5"/>
                    <measurement group_id="O3" value="92.1" spread="16.2"/>
                    <measurement group_id="O4" value="25.7" spread="23.9"/>
                    <measurement group_id="O5" value="172" spread="32.3"/>
                    <measurement group_id="O6" value="306" spread="28.7"/>
                    <measurement group_id="O7" value="30.2" spread="62.5"/>
                    <measurement group_id="O8" value="595" spread="27.9"/>
                    <measurement group_id="O9" value="71.9" spread="29.6"/>
                    <measurement group_id="O10" value="434" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax/D of Emodepside in Plasma</title>
        <description>Dose-normalized observed maximum plasma concentration (Cmax/D) was calculated as Cmax/Dose administered</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax/D of Emodepside in Plasma</title>
          <description>Dose-normalized observed maximum plasma concentration (Cmax/D) was calculated as Cmax/Dose administered</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>(ng/mL)/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="20.8"/>
                    <measurement group_id="O2" value="15.0" spread="15.5"/>
                    <measurement group_id="O3" value="18.4" spread="16.2"/>
                    <measurement group_id="O4" value="5.15" spread="23.9"/>
                    <measurement group_id="O5" value="17.2" spread="32.3"/>
                    <measurement group_id="O6" value="15.3" spread="28.7"/>
                    <measurement group_id="O7" value="1.51" spread="62.5"/>
                    <measurement group_id="O8" value="14.9" spread="27.9"/>
                    <measurement group_id="O9" value="71.9" spread="29.6"/>
                    <measurement group_id="O10" value="10.9" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax, Norm of Emodepside in Plasma</title>
        <description>The observed maximum plasma concentration (Cmax) normalized by dose and body weight was calculated as Cmax/(Dose administered*body weight)</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax, Norm of Emodepside in Plasma</title>
          <description>The observed maximum plasma concentration (Cmax) normalized by dose and body weight was calculated as Cmax/(Dose administered*body weight)</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>(ng/mL)/(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.265" spread="25.1"/>
                    <measurement group_id="O2" value="0.203" spread="25.2"/>
                    <measurement group_id="O3" value="0.244" spread="18.4"/>
                    <measurement group_id="O4" value="0.0680" spread="27.7"/>
                    <measurement group_id="O5" value="0.233" spread="46.7"/>
                    <measurement group_id="O6" value="0.189" spread="35.7"/>
                    <measurement group_id="O7" value="0.0187" spread="69.1"/>
                    <measurement group_id="O8" value="0.178" spread="36.3"/>
                    <measurement group_id="O9" value="0.0882" spread="28.9"/>
                    <measurement group_id="O10" value="0.133" spread="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tmax of Emodepside in Plasma</title>
        <description>Time to reach maximum plasma concentration (Tmax) was obtained directly from the concentration-time data</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived)</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax of Emodepside in Plasma</title>
          <description>Time to reach maximum plasma concentration (Tmax) was obtained directly from the concentration-time data</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived)</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="2.50"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.02" upper_limit="2.55"/>
                    <measurement group_id="O5" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.00" upper_limit="2.53"/>
                    <measurement group_id="O7" value="2.00" lower_limit="1.50" upper_limit="2.02"/>
                    <measurement group_id="O8" value="1.05" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O9" value="2.50" lower_limit="2.00" upper_limit="2.52"/>
                    <measurement group_id="O10" value="0.967" lower_limit="0.950" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The t½ of Emodepside in Plasma</title>
        <description>Terminal half-life (t½), calculated according to the equation t½ = ln2/λz, where λz is the apparent terminal elimination rate constant, estimated by linear regression of log-transformed concentration versus time data</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived)</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The t½ of Emodepside in Plasma</title>
          <description>Terminal half-life (t½), calculated according to the equation t½ = ln2/λz, where λz is the apparent terminal elimination rate constant, estimated by linear regression of log-transformed concentration versus time data</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived)</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="531"/>
                    <measurement group_id="O2" value="449" spread="74.0"/>
                    <measurement group_id="O3" value="415" spread="117"/>
                    <measurement group_id="O4" value="267" spread="392"/>
                    <measurement group_id="O5" value="365" spread="286"/>
                    <measurement group_id="O6" value="590" spread="68.1"/>
                    <measurement group_id="O7" value="348" spread="171"/>
                    <measurement group_id="O8" value="392" spread="31.7"/>
                    <measurement group_id="O9" value="531" spread="99.3"/>
                    <measurement group_id="O10" value="440" spread="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The MRT of Emodepside in Plasma</title>
        <description>The mean residence time (MRT) was calculated as MRT = AUMC/AUC∞, where AUMC is the area under the first moment of the concentration-time curve from zero time (pre-dose) extrapolated to infinite time</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The MRT of Emodepside in Plasma</title>
          <description>The mean residence time (MRT) was calculated as MRT = AUMC/AUC∞, where AUMC is the area under the first moment of the concentration-time curve from zero time (pre-dose) extrapolated to infinite time</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="528"/>
                    <measurement group_id="O2" value="572" spread="78.8"/>
                    <measurement group_id="O3" value="570" spread="92.1"/>
                    <measurement group_id="O4" value="337" spread="430"/>
                    <measurement group_id="O5" value="533" spread="232"/>
                    <measurement group_id="O6" value="757" spread="69.9"/>
                    <measurement group_id="O7" value="443" spread="182"/>
                    <measurement group_id="O8" value="489" spread="31.4"/>
                    <measurement group_id="O9" value="752" spread="91.7"/>
                    <measurement group_id="O10" value="569" spread="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The CL/F of Emodepside in Plasma</title>
        <description>Apparent total clearance from plasma (CL/F) was calculated as CL/F = Dose/AUC∞</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The CL/F of Emodepside in Plasma</title>
          <description>Apparent total clearance from plasma (CL/F) was calculated as CL/F = Dose/AUC∞</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>L/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="151"/>
                    <measurement group_id="O2" value="1.37" spread="44.1"/>
                    <measurement group_id="O3" value="1.34" spread="57.8"/>
                    <measurement group_id="O4" value="4.79" spread="179"/>
                    <measurement group_id="O5" value="1.42" spread="115"/>
                    <measurement group_id="O6" value="1.34" spread="24.8"/>
                    <measurement group_id="O7" value="13.3" spread="150"/>
                    <measurement group_id="O8" value="1.57" spread="32.6"/>
                    <measurement group_id="O9" value="1.42" spread="57.3"/>
                    <measurement group_id="O10" value="1.69" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC 0-24 of Emodepside in Plasma</title>
        <description>Area under the plasma concentration-time curve from time zero (pre-dose) to 24 h was calculated using the trapezoidal method</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC 0-24 of Emodepside in Plasma</title>
          <description>Area under the plasma concentration-time curve from time zero (pre-dose) to 24 h was calculated using the trapezoidal method</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="50.4"/>
                    <measurement group_id="O2" value="250" spread="6.50"/>
                    <measurement group_id="O3" value="522" spread="25.8"/>
                    <measurement group_id="O4" value="183" spread="24.3"/>
                    <measurement group_id="O5" value="996" spread="21.2"/>
                    <measurement group_id="O6" value="1910" spread="16.3"/>
                    <measurement group_id="O7" value="223" spread="58.0"/>
                    <measurement group_id="O8" value="4110" spread="33.6"/>
                    <measurement group_id="O9" value="673" spread="26.4"/>
                    <measurement group_id="O10" value="3320" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC 0-24/D of Emodepside in Plasma</title>
        <description>Dose-normalized area under the concentration-time curve (AUC) from time zero (pre-dose) to 24 h was calculated as AUC0-24/Dose administered</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC 0-24/D of Emodepside in Plasma</title>
          <description>Dose-normalized area under the concentration-time curve (AUC) from time zero (pre-dose) to 24 h was calculated as AUC0-24/Dose administered</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>(h.ng/mL)/mg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="50.4"/>
                    <measurement group_id="O2" value="100" spread="6.50"/>
                    <measurement group_id="O3" value="104" spread="25.8"/>
                    <measurement group_id="O4" value="36.5" spread="24.3"/>
                    <measurement group_id="O5" value="99.6" spread="21.2"/>
                    <measurement group_id="O6" value="95.3" spread="16.3"/>
                    <measurement group_id="O7" value="11.2" spread="58.0"/>
                    <measurement group_id="O8" value="103" spread="33.6"/>
                    <measurement group_id="O9" value="67.3" spread="26.4"/>
                    <measurement group_id="O10" value="82.9" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC 24, Norm of Emodepside in Plasma</title>
        <description>Area under the concentration-time curve from time zero (pre-dose) to 24 h, normalized by dose and body weight (AUC 24, norm) was calculated as AUC0-24/(Dose administered*body weight)</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC 24, Norm of Emodepside in Plasma</title>
          <description>Area under the concentration-time curve from time zero (pre-dose) to 24 h, normalized by dose and body weight (AUC 24, norm) was calculated as AUC0-24/(Dose administered*body weight)</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>(h*ng/mL)/(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="58.7"/>
                    <measurement group_id="O2" value="1.35" spread="17.5"/>
                    <measurement group_id="O3" value="1.38" spread="27.8"/>
                    <measurement group_id="O4" value="0.483" spread="28.9"/>
                    <measurement group_id="O5" value="1.35" spread="33.8"/>
                    <measurement group_id="O6" value="1.18" spread="27.8"/>
                    <measurement group_id="O7" value="0.138" spread="66.0"/>
                    <measurement group_id="O8" value="1.23" spread="42.9"/>
                    <measurement group_id="O9" value="0.825" spread="30.8"/>
                    <measurement group_id="O10" value="1.01" spread="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Vz/F of Emodepside in Plasma</title>
        <description>Apparent volume of distribution (Vz/F) was calculated as Vz/F = Dose/(λz × AUC∞), where λz is the apparent terminal elimination rate constant, estimated by linear regression of log-transformed concentration versus time data</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The Vz/F of Emodepside in Plasma</title>
          <description>Apparent volume of distribution (Vz/F) was calculated as Vz/F = Dose/(λz × AUC∞), where λz is the apparent terminal elimination rate constant, estimated by linear regression of log-transformed concentration versus time data</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>Litres</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" spread="88.0"/>
                    <measurement group_id="O2" value="885" spread="27.4"/>
                    <measurement group_id="O3" value="802" spread="49.1"/>
                    <measurement group_id="O4" value="1850" spread="56.1"/>
                    <measurement group_id="O5" value="748" spread="68.7"/>
                    <measurement group_id="O6" value="1140" spread="47.1"/>
                    <measurement group_id="O7" value="6700" spread="40.1"/>
                    <measurement group_id="O8" value="888" spread="21.3"/>
                    <measurement group_id="O9" value="1090" spread="36.2"/>
                    <measurement group_id="O10" value="1070" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC Last of Emodepside in Plasma</title>
        <description>The area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t), calculated using the linear trapezoidal method for increasing concentrations and the log trapezoidal method for decreasing concentrations</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC Last of Emodepside in Plasma</title>
          <description>The area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t), calculated using the linear trapezoidal method for increasing concentrations and the log trapezoidal method for decreasing concentrations</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182" spread="111"/>
                    <measurement group_id="O2" value="845" spread="10.4"/>
                    <measurement group_id="O3" value="1700" spread="24.2"/>
                    <measurement group_id="O4" value="501" spread="76.8"/>
                    <measurement group_id="O5" value="3070" spread="27.7"/>
                    <measurement group_id="O6" value="7480" spread="22.1"/>
                    <measurement group_id="O7" value="667" spread="125"/>
                    <measurement group_id="O8" value="16400" spread="23.6"/>
                    <measurement group_id="O9" value="3390" spread="20.4"/>
                    <measurement group_id="O10" value="13800" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frel of the IR (Immediate Release) Tablet of Emodepside</title>
        <description>The average relative bioavailability (Frel) of the IR tablet was calculated</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 5mg Solution Versus Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution versus tablet, administered in fasted state Part one of study</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 20mg Solution Versus Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution versus tablet, administered in fasted state Part one of study</description>
          </group>
        </group_list>
        <measure>
          <title>Frel of the IR (Immediate Release) Tablet of Emodepside</title>
          <description>The average relative bioavailability (Frel) of the IR tablet was calculated</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>Frel percentage</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" lower_limit="26.6" upper_limit="46.0"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7.73" upper_limit="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC Last, Norm of Emodepside in Plasma</title>
        <description>The area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration normalized by dose and body weight (AUClast/(Dose administered*body weight))</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O3">
            <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O4">
            <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O5">
            <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O6">
            <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O7">
            <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O8">
            <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
          <group group_id="O9">
            <title>Emodepside 10mg Solution, Fed (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O10">
            <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
            <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
          </group>
          <group group_id="O11">
            <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
            <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC Last, Norm of Emodepside in Plasma</title>
          <description>The area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration normalized by dose and body weight (AUClast/(Dose administered*body weight))</description>
          <population>PK Concentration data were summarized using the PK concentration population (all subjects who received at least one dose of study drug and for whom a PK sample was analyzed). PK parameters were summarized using the PK Parameter population (all subjects in the PK Concentration Population for whom PK parameters could be derived).</population>
          <units>(h*ng/mL)/(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="127"/>
                    <measurement group_id="O2" value="4.56" spread="19.5"/>
                    <measurement group_id="O3" value="4.50" spread="27.1"/>
                    <measurement group_id="O4" value="1.33" spread="78.4"/>
                    <measurement group_id="O5" value="4.17" spread="42.6"/>
                    <measurement group_id="O6" value="4.62" spread="30.8"/>
                    <measurement group_id="O7" value="0.414" spread="138"/>
                    <measurement group_id="O8" value="4.91" spread="36.5"/>
                    <measurement group_id="O9" value="4.16" spread="25.5"/>
                    <measurement group_id="O10" value="4.21" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on the Bioavailability (Cmax) of Emodepside (BAY 44-4400) After Single Oral Dose Administered as Solution or IR Tablets in One Arm Only</title>
        <description>Results of the statistical analysis of the effect of food on Emodepside exposure, after a single dose of 10 mg Emodepside LSF solution.</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>emodepside assessed in fasted condition: only one cohort (10mg solution) assessed with high fat high calories meal.</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 10mg Solution Fasted</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 10mg Solution Fed</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on the Bioavailability (Cmax) of Emodepside (BAY 44-4400) After Single Oral Dose Administered as Solution or IR Tablets in One Arm Only</title>
          <description>Results of the statistical analysis of the effect of food on Emodepside exposure, after a single dose of 10 mg Emodepside LSF solution.</description>
          <population>emodepside assessed in fasted condition: only one cohort (10mg solution) assessed with high fat high calories meal.</population>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" lower_limit="96.7" upper_limit="227.0"/>
                    <measurement group_id="O2" value="71.9" lower_limit="47.4" upper_limit="109.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on the Bioavailability (AUC24) of Emodepside (BAY 44-4400) After Single Oral Dose Administered as Solution or IR Tablets in One Arm Only</title>
        <description>Results of the statistical analysis of the effect of food on Emodepside exposure, after a single dose of 10 mg Emodepside LSF solution.</description>
        <time_frame>From pre-dose until 336h post-dose (may be extended to 504h post-dose)</time_frame>
        <population>emodepside assessed in fasted condition: only one cohort (10mg solution) assessed with high fat high calories meal.</population>
        <group_list>
          <group group_id="O1">
            <title>Emodepside 10mg Solution Fasted</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Emodepside 10mg Solution Fed</title>
            <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on the Bioavailability (AUC24) of Emodepside (BAY 44-4400) After Single Oral Dose Administered as Solution or IR Tablets in One Arm Only</title>
          <description>Results of the statistical analysis of the effect of food on Emodepside exposure, after a single dose of 10 mg Emodepside LSF solution.</description>
          <population>emodepside assessed in fasted condition: only one cohort (10mg solution) assessed with high fat high calories meal.</population>
          <units>ng*h/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="996" lower_limit="753" upper_limit="1380"/>
                    <measurement group_id="O2" value="673" lower_limit="520" upper_limit="982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AE reporting period for this trial began after subject enrolment in the trial (after signature of informed consent) and ended at the follow-up visit (3 weeks after their dose of study medicine) .</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Emodepside 0.1mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 0.1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E2">
          <title>Emodepside 1mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 1mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E3">
          <title>Emodepside 2.5mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 2.5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E4">
          <title>Emodepside 5mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 5mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E5">
          <title>Emodepside 5mg Tablet, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 5mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E6">
          <title>Emodepside 10mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E7">
          <title>Emodepside 20mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 20mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E8">
          <title>Emodepside 20mg Tablet, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 20mg tablet (immediate release), administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E9">
          <title>Emodepside 40mg Solution, Fasted (Part 1)</title>
          <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E10">
          <title>Emodepside 10mg Solution, Fed (Part 2)</title>
          <description>Emodepside (BAY 44-4400) 10mg solution, as oral liquid service formulation, administered in fed state This cohort was not classed as first in human Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="E11">
          <title>Emodepside 40mg Solution, Fasted, (Part 2)</title>
          <description>Emodepside (BAY 44-4400) 40mg solution, as oral liquid service formulation, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="E12">
          <title>Placebo Solution, Fasted (Part 1)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E13">
          <title>Placebo Tablet, Fasted (Part 1)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), tablet, administered in fasted state Part one of study (FIH, single ascending dose phase)</description>
        </group>
        <group group_id="E14">
          <title>Placebo Solution, Fed (Part 2)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fed state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
        <group group_id="E15">
          <title>Placebo Solution, Fasted (Part 2)</title>
          <description>Matching placebo of emodepside (BAY 44-4400), solution, administered in fasted state Part two of study (not FIH, exploratory effect of food on the bioavailability of emodepside and to assess relationship between emodepside and adverse events)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>TEAEs by primary system organ classes (SOCs)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution (HMR) could not make any public communication related to the Results or Trial Subjects, notably, without DNDi's prior written approval. The Institution shall inform DNDi in advance of any media visits to the Clinical Trial site and comply with the guidance provided by DNDi.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sophie Delhomme</name_or_title>
      <organization>Drugs for Neglected Diseases initiative</organization>
      <phone>+41229069230</phone>
      <email>sdelhomme@dndi.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

